|Chemical and physical data|
|Molar mass||282.37678 g/mol|
|3D model (Jmol)||Interactive image|
Mestilbol (brand name Monomestro or Monomestrol), also known as diethylstilbestrol monomethyl ether, is a synthetic, non-steroidal estrogen of the stilbestrol group related to diethylstilbestrol. It was developed by Wallace & Tiernan Company, patented in 1940, and introduced for medical use in the 1940s, but is now no longer marketed. Mestilbol was available both as oral tablets and in oil for intramuscular injection. The drug is gradually demethylated in the body into diethylstilbestrol and hence is a prodrug of diethylstilbestrol. Mestilbol is a highly active estrogen, although somewhat less so than diethylstilbestrol, but is longer-lasting in comparison.
- J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 396. ISBN 978-1-4757-2085-3.
- Martin Negwer (1987). Organic-chemical drugs and their synonyms: (an international survey). VCH Publishers. p. 923. ISBN 978-0-89573-552-2.
- Council on Drugs (American Medical Association) (1955). New and Nonofficial Drugs. Lippincott. pp. 419–420.
- Sevringhaus, Elmer L. (1944). "Therapy of the Patient in the Menopause: Endocrine Methods". The Journal of Clinical Endocrinology & Metabolism. 4 (12): 597–604. doi:10.1210/jcem-4-12-597. ISSN 0021-972X.
- Postgraduate Medicine. McGraw-Hill. 1949. p. 347.
- Annales de Bourgogne. Centre d'études bourguignonnes. 1940.
- Russell La Fayette Cecil; Robert Frederick Loeb (1951). A Textbook of Medicine. Saunders.
- William Thomas Salter (1952). A Textbook of Pharmacology: Principles and Application of Pharmacology to the Practice of Medicine. Saunders.